Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Head and Neck Neoplasms 150Squamous Cell Carcinoma of Head and Neck 136Stomach Neoplasms 117Lung Neoplasms 109Esophageal Neoplasms 90Uterine Cervical Neoplasms 72Neoplasms 67Urinary Bladder Neoplasms 56Breast Neoplasms 48Ovarian Neoplasms 46Esophageal Squamous Cell Carcinoma 45Pancreatic Neoplasms 44Small Cell Lung Carcinoma 42Neoplasm Metastasis 40Adenocarcinoma Of Esophagus 38Carcinoma, Squamous Cell 33Carcinoma, Ovarian Epithelial 32Mesothelioma, Malignant 30Parkinson Disease 4, Autosomal Dominant Lewy Body 28Lymphoma 28Adenocarcinoma of Lung 25Sarcoma 24Cholangiocarcinoma 24Nasopharyngeal Carcinoma 22Carcinoma 22Unspecified Adult Solid Tumor, Protocol Specific 21Neuroblastoma 21Gallbladder Neoplasms 21Central Nervous System Neoplasms 21

Interventions

Capecitabine 3Trastuzumab 2Temozolomide 2Streptozocin 2Leucovorin 2Fluorouracil 2vatalanib 1tipifarnib 1regorafenib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Oxaliplatin 1Omeprazole 1Octreotide 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gefitinib 1Floxuridine 1Fentanyl 1Everolimus 1Doxorubicin 1Cisplatin 1Bortezomib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrinoma × Cisplatin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡